The strong and beneficial response would be presented in patients with the abundance of F. prausnitzii receiving anti-CTLA-4 and/or anti-PD-1 inhibitors, possibly with the cost of immunotherapy-induced colitis. This evidence concerns the gene PDCD1 and colitis.